Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1187.57
CLRB's Cash-to-Debt is ranked higher than
57% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CLRB: 1187.57 )
Ranked among companies with meaningful Cash-to-Debt only.
CLRB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 121.76 Max: No Debt
Current: 1187.57
Interest Coverage N/A
CLRB's Interest Coverage is ranked lower than
57% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CLRB: N/A )
Ranked among companies with meaningful Interest Coverage only.
CLRB' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 3
Altman Z-Score: -2.04
Beneish M-Score: 17.78
WACC vs ROIC
13.01%
-479.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -97.71
CLRB's ROE % is ranked lower than
79% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CLRB: -97.71 )
Ranked among companies with meaningful ROE % only.
CLRB' s ROE % Range Over the Past 10 Years
Min: -1254.05  Med: -154.65 Max: -81.37
Current: -97.71
-1254.05
-81.37
ROA % -85.18
CLRB's ROA % is ranked lower than
81% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. CLRB: -85.18 )
Ranked among companies with meaningful ROA % only.
CLRB' s ROA % Range Over the Past 10 Years
Min: -428.41  Med: -88.3 Max: -52.29
Current: -85.18
-428.41
-52.29
ROC (Joel Greenblatt) % -747.12
CLRB's ROC (Joel Greenblatt) % is ranked lower than
57% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. CLRB: -747.12 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CLRB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -36463.74  Med: -480.55 Max: -221.48
Current: -747.12
-36463.74
-221.48
3-Year EBITDA Growth Rate -64.00
CLRB's 3-Year EBITDA Growth Rate is ranked lower than
87% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CLRB: -64.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CLRB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -85.9  Med: -35.5 Max: 48.3
Current: -64
-85.9
48.3
3-Year EPS without NRI Growth Rate -67.20
CLRB's 3-Year EPS without NRI Growth Rate is ranked lower than
90% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CLRB: -67.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CLRB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -85.8  Med: -46.5 Max: 242
Current: -67.2
-85.8
242
» CLRB's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NAS:CLRB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:EMIS, AMEX:BPMX, NAS:PTIE, NAS:OCRX, TSXV:DMA, AMEX:CRMD, NAS:DFFN, NAS:CAPR, NAS:VICL, OTCPK:SNBP, OTCPK:MRNA, OTCPK:CELZ, AMEX:IBIO, NAS:HTBX, NAS:XBIO, NAS:JAGX, NAS:AVIR, OTCPK:PRTX, NAS:EYEG, OTCPK:QRON » details
Traded in other countries:NV4N.Germany,
Headquarter Location:USA
Cellectar Biosciences Inc is a biopharmaceutical company. It is engaged in developing compounds for treatment and imaging of cancer. Its portfolio consists of PET imaging agents, optical imaging agents, and therapeutic agents.

Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.

Ratios

vs
industry
vs
history
PB Ratio 2.25
CLRB's PB Ratio is ranked higher than
82% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CLRB: 2.25 )
Ranked among companies with meaningful PB Ratio only.
CLRB' s PB Ratio Range Over the Past 10 Years
Min: 0.09  Med: 5.22 Max: 95.91
Current: 2.25
0.09
95.91
EV-to-EBIT -1.49
CLRB's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CLRB: -1.49 )
Ranked among companies with meaningful EV-to-EBIT only.
CLRB' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.9  Med: -1.5 Max: -0.1
Current: -1.49
-31.9
-0.1
EV-to-EBITDA -1.54
CLRB's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CLRB: -1.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
CLRB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -32.9  Med: -1.7 Max: -0.1
Current: -1.54
-32.9
-0.1
Current Ratio 5.88
CLRB's Current Ratio is ranked higher than
75% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CLRB: 5.88 )
Ranked among companies with meaningful Current Ratio only.
CLRB' s Current Ratio Range Over the Past 10 Years
Min: 0.21  Med: 1.57 Max: 37.44
Current: 5.88
0.21
37.44
Quick Ratio 5.88
CLRB's Quick Ratio is ranked higher than
76% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CLRB: 5.88 )
Ranked among companies with meaningful Quick Ratio only.
CLRB' s Quick Ratio Range Over the Past 10 Years
Min: 0.21  Med: 1.57 Max: 37.44
Current: 5.88
0.21
37.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -229.50
CLRB's 3-Year Average Share Buyback Ratio is ranked lower than
87% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CLRB: -229.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLRB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -464.6  Med: -115.4 Max: 0
Current: -229.5
-464.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.65
CLRB's Price-to-Net-Cash is ranked higher than
84% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. CLRB: 3.65 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CLRB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.31  Med: 6.46 Max: 67.02
Current: 3.65
1.31
67.02
Price-to-Net-Current-Asset-Value 3.20
CLRB's Price-to-Net-Current-Asset-Value is ranked higher than
86% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CLRB: 3.20 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CLRB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.33  Med: 8.22 Max: 76.6
Current: 3.2
1.33
76.6
Price-to-Tangible-Book 2.63
CLRB's Price-to-Tangible-Book is ranked higher than
83% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CLRB: 2.63 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CLRB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.15  Med: 4.9 Max: 860.47
Current: 2.63
1.15
860.47
Earnings Yield (Greenblatt) % -67.13
CLRB's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CLRB: -67.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CLRB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -746.4  Med: -65.05 Max: -3.1
Current: -67.13
-746.4
-3.1

More Statistics

EPS (TTM) $ -1.24
Beta1.82
Short Percentage of Float11.35%
52-Week Range $1.12 - 3.19
Shares Outstanding (Mil)13.92
» More Articles for NAS:CLRB

Headlines

Articles On GuruFocus.com
Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Sep 21 2017 
Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference Sep 20 2017 
Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer Sep 18 2017 
Cellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference Sep 06 2017 
Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Impr Aug 22 2017 
Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance Aug 14 2017 
Cellectar Biosciences’ CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Aug 08 2017 
Cellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017 Fina Aug 03 2017 
Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumor Aug 01 2017 
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cellectar Biosciences, Inc. for Po Jun 15 2017 

More From Other Websites
Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New... Sep 21 2017
Cellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference Sep 20 2017
Cellectar Biosciences Appoints Jarrod Longcor Chief Business Officer Sep 18 2017
Cellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference Sep 06 2017
Cellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to... Aug 22 2017
Edited Transcript of CLRB earnings conference call or presentation 14-Aug-17 9:00pm GMT Aug 15 2017
Cellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance Aug 14 2017
Cellectar Biosciences’ CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced... Aug 08 2017
Cellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017... Aug 03 2017
Cellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid... Aug 01 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cellectar Biosciences, Inc. for... Jun 15 2017
Edited Transcript of CLRB earnings conference call or presentation 11-May-17 8:30pm GMT May 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}